BioTime, Inc. to Announce First Quarter 2017 Results on May 10, 2017
Conference Call and Webcast on Wednesday, May 10, 2017, at 4:30 p.m.
ET / 1:30 p.m. PT
ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 26, 2017--
BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company
developing and commercializing products addressing degenerative
diseases, today announced that it will release first quarter financial
and operating results on Wednesday, May 10, 2017, after the close of the
U.S. financial markets. The Company will host a conference call and
webcast on Wednesday, May 10, 2017, at 4:30 p.m. Eastern Time / 1:30
p.m. Pacific Time to discuss the results and recent corporate
The conference call dial-in number in the U.S./Canada is 1-877-
407-0784. For international participants outside the U.S./Canada, the
dial-in number is 1-201 689-8560. For all callers, please refer to the
“BioTime, Inc. Conference Call.” The live webcast can be accessed on the
“Events & Presentations” page of the “Investors & Media” section on the
company’s website at http://www.biotimeinc.com/.
A replay of the conference call will be available for seven business
days beginning about two hours after the conclusion of the live call, by
calling toll-free from U.S./Canada: 1-844-512-2921; international
callers dial 1-412-317-6671. Use the Conference ID 13661114.
Additionally, the archived webcast will be available on the “Events &
Presentations” page of the “Investors & Media” section on the company’s
website at http://www.biotimeinc.com/.
BioTime, Inc. is a clinical-stage biotechnology company focused on
developing and commercializing novel therapies developed from what the
company believes to be the world’s premier collection of pluripotent
cell assets. The foundation of BioTime’s core therapeutic technology
platform is pluripotent cells that are capable of becoming any of the
cell types in the human body. Pluripotent cells have potential
application in many areas of medicine with large unmet patient needs,
including various age-related degenerative diseases and degenerative
conditions for which there presently are no cures. Unlike
pharmaceuticals that require a molecular target, therapeutic strategies
based on the use of pluripotent cells are generally aimed at
regenerating or replacing affected cells and tissues, and therefore may
have broader applicability than pharmaceutical products. BioTime also
has significant equity holdings in two publicly traded
companies, Asterias Biotherapeutics, Inc. and OncoCyte Corporation,
which BioTime founded and which, until recently, were majority-owned
consolidated subsidiaries of BioTime.
BioTime common stock is traded on the NYSE MKT and TASE under the symbol
BTX. For more information, please visit www.biotimeinc.com
or connect with the company on Twitter,
To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list: http://news.biotimeinc.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170426005476/en/
Source: BioTime, Inc.
EVC Group, Inc.
Brian Moore, 310-770-0389
Gotham Communications, LLC
Bill Douglass, 646-504-0890